Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PGK1 | P00558 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753190 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL615403 | 0.84 | GAA (0.72) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL25245233 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL6968277 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL24603548 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL25293759 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL30626920 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL30973163 | 0.81 | GAA (0.68) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL6175757 | 0.81 | GAA (0.46) | SMN1; SMN2HTTMAPTGAARAB9A | |
| SCHEMBL9455529 | 0.81 | LMNA (0.52) | SMN1; SMN2HTTMAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753730-A | Method for preparing 2-amino-4-chloro-5-nitrophenol | 宜兴市新宇化工有限公司 | 2016-07-13 | — | — | CN | claimed |
| CN-117088869-A | 3CL protease inhibitor and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-105753730-A | Method for preparing 2-amino-4-chloro-5-nitrophenol | 宜兴市新宇化工有限公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-102040552-A | 1, 2-di (cyclic group) substituted benzene derivative | EISAI R&D MAN CO LTD | 2011-05-04 | — | — | CN | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| CN-101175723-A | 1, 2-di (cyclic group) substituted benzene derivative | EISAI R&D MAN CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | SMN1; SMN2 4289/4885HTT 3024/4885MAPT 4564/4885 |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | SMN1; SMN2 3987/4885HTT 2786/4885MAPT 4459/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | SMN1; SMN2 1754/4885HTT 2097/4885MAPT 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.